Literature DB >> 18923657

Contrast media-induced nephropathy: case report and review of the literature focusing on pathogenesis.

G Efstratiadis1, P Pateinakis, G Tambakoudis, A Pantzaki, D Economidou, D Memmos.   

Abstract

Contrast media administration during diagnostic and invasive procedures in high risk patients for nephrotoxicity is a common problem in clinical practice. The mechanisms involved in renal function impairment after contrast media administration are not precisely known but are intensively investigated, and new data have emerged in the literature lately. We present the case of a 72-year old male patient with diabetic nephropathy to whom a new generation iso-osmolar contrast medium (iodixanol) was administered during intravenous pyelography. Due to the contrast agent administration, the patient developed irreversible acute renal failure and became dialysis-dependent. This case suggests that even new generation contrast media (including iodixanol) may be severely nephrotoxic, when administered to high risk patients. Additionally we review the complex mechanisms involved in pathogenesis of contrast media nephrotoxicity.

Entities:  

Keywords:  acute renal failure; contrast media; diabetes mellitus; nephrotoxicity

Year:  2008        PMID: 18923657      PMCID: PMC2464306     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  43 in total

1.  ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions.

Authors:  P J Scanlon; D P Faxon; A M Audet; B Carabello; G J Dehmer; K A Eagle; R D Legako; D F Leon; J A Murray; S E Nissen; C J Pepine; R M Watson; J L Ritchie; R J Gibbons; M D Cheitlin; T J Gardner; A Garson; R O Russell; T J Ryan; S C Smith
Journal:  J Am Coll Cardiol       Date:  1999-05       Impact factor: 24.094

2.  Contrast-agent-induced acute renal dysfunction--is iodixanol the answer?

Authors:  Carl M Sandler
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

3.  Contrast-associated nephropathy--old clinical problem and new therapeutic perspectives.

Authors:  A Kolonko; F Kokot; A Wiecek
Journal:  Nephrol Dial Transplant       Date:  1998-03       Impact factor: 5.992

4.  Comparison of iodixanol and iohexol in renal impairment.

Authors:  N Chalmers; R W Jackson
Journal:  Br J Radiol       Date:  1999-07       Impact factor: 3.039

Review 5.  Renal haemodynamic alterations in contrast medium-induced nephropathy and the benefit of hydration.

Authors:  Pontus B Persson; Andreas Patzak
Journal:  Nephrol Dial Transplant       Date:  2005-02       Impact factor: 5.992

6.  Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism.

Authors:  A Wang; T Holcslaw; T M Bashore; M I Freed; D Miller; M R Rudnick; H Szerlip; M D Thames; C J Davidson; N Shusterman; S J Schwab
Journal:  Kidney Int       Date:  2000-04       Impact factor: 10.612

Review 7.  Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality.

Authors:  Michael R Rudnick; Stanley Goldfarb
Journal:  Rev Cardiovasc Med       Date:  2003       Impact factor: 2.930

8.  Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity.

Authors:  Richard A Zager; Ali C M Johnson; Sherry Y Hanson
Journal:  Kidney Int       Date:  2003-07       Impact factor: 10.612

9.  Radiocontrast agents induce endothelin release in vivo and in vitro.

Authors:  S N Heyman; B A Clark; N Kaiser; K Spokes; S Rosen; M Brezis; F H Epstein
Journal:  J Am Soc Nephrol       Date:  1992-07       Impact factor: 10.121

10.  Et-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia.

Authors:  P Liss; P-O Carlsson; A Nygren; F Palm; P Hansell
Journal:  Acta Radiol       Date:  2003-01       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.